NBL-CY01-P
CYTOKINE-ENGINEERED BIOLOGICS FOR ANGIOGENESIS
NBL-CY01-P
CYTOKINE-ENGINEERED BIOLOGICS FOR ANGIOGENESIS
NBL-CY01-P
Cytokine-Engineered Biologics For Angiogenesis
NBL-CY01-P is an engineered cytokine therapy designed to stimulate angiogenesis and reduce inflammation in ischemic vascular diseases. By enhancing Type II cytokine targeted downstream pathways, this novel biologic promotes blood vessel growth and tissue repair without the need for cell transplantation. As an off-the-shelf injectable, NBL-CY01-P offers a scalable, cell-free alternative for treating conditions such as PAD, diabetic ulcers, and myocardial ischemia.
Indication
Ischemic vascular diseases beyond PAD/CLI (e.g., diabetic foot ulcer, myocardial ischemia).
Technology
Self-engineered cytokines as standalone or combination biologics to boost angiogenesis and reduce inflammation. Off-the-shelf and scalable
Format
Homologous injection
